Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival.
Hari P, Reece DE, Randhawa J, Flomenberg N, Howard DS, Badros AZ, Rapoport AP, Meisenberg BR, Filicko-Ohara J, Phillips GL, Vesole DH. Hari P, et al. Among authors: vesole dh. Bone Marrow Transplant. 2019 Feb;54(2):293-299. doi: 10.1038/s41409-018-0261-y. Epub 2018 Jun 15. Bone Marrow Transplant. 2019. PMID: 29907806 Clinical Trial.
Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.
Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Bladé J, et al. Br J Haematol. 1998 Sep;102(5):1115-23. doi: 10.1046/j.1365-2141.1998.00930.x. Br J Haematol. 1998. PMID: 9753033 Free article. No abstract available.
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.
Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J. Desikan R, et al. Blood. 2000 Jun 15;95(12):4008-10. Blood. 2000. PMID: 10845942 Free article. Clinical Trial.
Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts.
Drobyski WR, Klein J, Flomenberg N, Pietryga D, Vesole DH, Margolis DA, Keever-Taylor CA. Drobyski WR, et al. Among authors: vesole dh. Blood. 2002 Feb 1;99(3):806-14. doi: 10.1182/blood.v99.3.806. Blood. 2002. PMID: 11806980 Free article.
Multiple myeloma: role of allogeneic transplantation.
Pandit S, Vesole DH. Pandit S, et al. Among authors: vesole dh. Oncology (Williston Park). 2002 Sep;16(9):1268-74; discussion 1274-6. Oncology (Williston Park). 2002. PMID: 12380950 Free article. Review.
262 results